Results 41 to 50 of about 355,053 (311)

Pylorus‐Preserving Gastrectomy for Gastric Cancer: Current Evidence and Future Directions

Annals of Gastroenterological Surgery, EarlyView.
This review aims to outline the current evidence and future directions of PPG, focusing on the feasibility of extending its application beyond its traditional indications. ABSTRACT Pylorus‐preserving gastrectomy (PPG) is a function‐preserving surgery for clinically T1N0M0 (cT1N0M0) early gastric cancer (EGC) located in the middle third of the stomach ...
Sa‐Hong Kim, Hyuk‐Joon Lee
wiley   +1 more source

BOTULINUM TOXIN IN OPHTHALMOLOGY [PDF]

Australian and New Zealand Journal of Ophthalmology, 1988
AbstractAlan B. Scott selected, researched and developed Type A Botulinum toxin for clinical use in ophthalmology. This unique drug has proved invaluable for treatment of a number of conditions which are difficult to treat in ophthalmology and in a variety of other disciplines.
D, Dunlop, G, Pittar, C, Dunlop
openaire   +2 more sources

Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: Updated review

Journal of Cosmetic Dermatology, 2018
Botulinum Toxin Type A is a potent neurotoxin that is produced by a gram‐positive bacteria clostridium botulinum. Its utilization in the treatment of various medical condition has expanded over the years in both medical and esthetic uses.
Lorna Martin Kasyanju Carrero, Wei-wei Ma, Houfang Liu, Xufeng Yin, Bingrong Zhou   +4 more
semanticscholar   +1 more source

The 9th International RASopathies Symposium

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT The RASopathies are a group of congenital disorders with overlapping clinical manifestations that are caused by pathogenic germline or early somatic variants that result in the hyperactivation of the RAS/mitogen‐activated protein kinase (MAPK) signaling pathway.
Pau Castel, Lisa Schoyer, Beth Stronach, Raya Bogdanova, Anton M. Bennett, Jaishri Blakeley, Miriam Bornhorst, Tammy Bowers, Saskia M. Brachmann, Emma Burkitt‐Wright, Kathryn Chatfield, Alessandro De Luca, Khalil El‐Chammas, Abdul Elkadri, John E. Fortunato, Bruce D. Gelb, Anne Goriely, Karen Gripp, Kassidy Grover, Lindsay Homan, Kenneth A. Kern, Maija Kiuru, Charles (Chuck) Lawson, Yong‐Seok Lee, Frank McCormick, Gina Ney, Cristina Nuevo‐Tapioles, Sara Pardej, Elizabeth I. Pierpont, Julia Plank, Nancy Ratner, Katherine A. Rauen, J. Elliott Robinson, Les Rogers, Sarah E. Sheppard, Keir Shiels, David Stevenson, Dagmar Tiemens, Matthew Traylor, K. Nicole Weaver, Marielle Yohe, Tamar Green   +41 more
wiley   +1 more source

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway, Cinzia Dello Russo, Nicholas Bass, Elvira Bramon, Helen Cross, Natalie Curley, Sarah Curran, Helen Davies, Jana De Villiers, William Evans, Bernhard Frank, Alice Groves, Judith Hayward, Jon Higham, Dyfrig A. Hughes, Shwe Sin Kyaw, Anthony G. Marson, Ailsa McLellan, Seth Mensah, Francis O'Neill, Jane Sargison, Sanjay M. Sisodiya, Jill Swan, Joanna M. Zakrewska, Munir Pirmohamed   +24 more
wiley   +1 more source

THE EMERGING ROLE OF BOTULINUM TOXIN IN THE TREATMENT OF OROFACIAL DISORDERS: LITERATURE UPDATE

, 2017
Botulinum toxin (BTX) is a lethal neurotoxin produced by Gram-positive anaerobic bacterium called Clostridium botulinum . It is the first toxin used fortherapeutic purposes since 1989.
Santhosh Kumar
semanticscholar   +1 more source

The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon

Arthritis & Rheumatology, 2017
To assess the therapeutic efficacy of local injections of botulinum toxin type A (Btx‐A) in improving blood flow to the hands of patients with Raynaud's phenomenon (RP) secondary to scleroderma.
Ricardo J. Bello, C. Cooney, E. Melamed, K. Follmar, G. Yenokyan, G. Leatherman, Ami A. Shah, Fredrick M. Wigley, L. Hummers, Scott D Lifchez   +9 more
semanticscholar   +1 more source

Biomaterials for modulating cellular responses of endogenous tendon stem/progenitor cells: A promising avenue for tendon regeneration

BMEMat, EarlyView.
This review comprehensively summarizes emerging biomaterial‐based strategies and underlying mechanisms for modulating endogenous tendon stem/progenitor cells (TSPCs). It offers the most recent insights into TSPC physiology and potential applications of tissue engineering and regenerative medicine in tendons.
Zeyu Zhu, Renwang Sheng, Mumin Cao, Ludvig J. Backman, Yucheng Gao, Hao Wang, Cheng Zhang, Jialin Chen, Wei Zhang, Yunfeng Rui   +9 more
wiley   +1 more source

Positional Relationship Between the Orbicularis Oculi and Zygomaticus Complex Muscles by Ultrasonography: New Anatomical Insights for Crow's Feet Injection

Clinical Anatomy, EarlyView.
ABSTRACT The orbicularis oculi muscle (OOc) is strongly associated with facial aging as its contraction causes the formation of crow's feet. Botulinum neurotoxin (BoNT) injection is a representative treatment targeting muscle. The aim of this study was to demonstrate the anatomical relationship between the OOc and the zygomaticus complex muscles, and ...
Jiong‐Zhen Piao, Ji‐Hyun Lee, Kyung‐Seok Hu, Hee‐Jin Kim   +3 more
wiley   +1 more source

Therapeutic use of botulinum toxin in pain treatment

Neuronal Signaling, 2018
Botulinum toxin is one of the most potent molecule known to mankind. A neurotoxin, with high affinity for cholinergic synapse, is effectively capable of inhibiting the release of acetylcholine.
Raj Kumar
semanticscholar   +1 more source